Compare BridgeBio Pharma Inc (BBIO) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Toronto-Dominion Bank — how do they compare? BridgeBio Pharma Inc trades at $82.55 (market cap $16.46B), while Toronto-Dominion Bank trades at $123.55 (market cap $198.63B). The key difference: Toronto-Dominion Bank is far larger — about 12.1× BridgeBio Pharma Inc's market cap, and Toronto-Dominion Bank pays a 2.62% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | TD | |
|---|---|---|
Market Cap | $16.46B | $198.63B |
Sector | Health | Financials |
52-Week High | $90.17 | $122.88 |
52-Week Low | $44.81 | $72.55 |
Enterprise Value | $18.02B | — |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
TD trades at $120.63, up 0.08% today, with a bullish technical signal from moving averages and a consensus analyst price target of $153.00. The company has beaten EPS estimates for three consecutive quarters, with Q2 2026 results pending. Revenue grew to $61.28 billion in 2025, and net income margin improved to 33.51%. Recent news highlights strong Q2 2026 earnings and a dividend increase.
The outlook is positive, supported by earnings momentum, a high analyst buy rating (52.94%), and operational efficiency gains from AI. Key risks include volatile cash flows, high debt levels, and economic sensitivity. The stock offers a solid dividend and growth potential, but investors should monitor credit performance and interest rate impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
